PLPavel Andreevich Levkin

Pavel Andreevich Levkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pavel Andreevich Levkin has a total of 557 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    S‐Nitrosothiols as Thiol‐Protecting Groups for Controlled Thiol‐Maleimide Crosslinking of Homogeneous Soft Hydrogels

    by Julian A. Serna, Michelle J. Iwohn, Maximilian Seifermann, Stefan Heißler, Maike Schliephake, Franziska Dopp, Claudia Muhle‐Goll, Pavel A. Levkin

    The thiol‐maleimide Michael‐type addition is used in bioconjugation and hydrogel crosslinking for its chemoselectivity and rapid kinetics under physiological conditions. However, this same reactivity limits its use for soft hydrogels, as gelation often proceeds faster than precursor mixing, leading to spatially heterogeneous networks. Here, S‐nitrosothiols (RSNOs) are introduced as thiol‐protecting groups that suppress premature thiol‐maleimide coupling and enable homogeneous mixing of polymer precursors prior to on‐demand crosslinking. Despite common assumptions about RSNO instability, RSNO‐modified 4‐arm polyethylene glycol (PEGSNO) is stable in aqueous solution for months at 4°C protected from light. The nucleophiles sodium ascorbate or sodium thiosulfate (STS) trigger thiol regeneration and controlled crosslinking with maleimide‐modified PEG. The resulting hydrogels are homogeneous with Young's moduli tunable across a physiologically relevant range by independently varying nucleophile identity, concentration, or polymer content. In a cell‐adhesive system based on maleimide‐modified cold water fish skin gelatin, STS‐triggered gelation supports 3D cell encapsulation, with cytocompatibility depending on formulation and cell type, while matrix stiffness is tuned through polymer content and STS concentration. This work establishes RSNO chemistry as a previously unexplored strategy for controlled thiol‐maleimide crosslinking, enabling reproducible, homogeneous network formation, with potential for dual‐function materials coupling network formation with local reactive nitrogen species delivery.

  • Open Access

    Ultra‐High‐Throughput Discovery of Multifunctional Polyphenolic Coatings on Droplet Microarrays

    by Vania Tanda Widyaya, Joaquín E. Urrutia Gómez, Paul Reuß, Alexander Welle, Rolf A. Gattung, Jana Mayer, Peter Krolla, Markus Reischl, Pascal Friederich, Anna A. Popova, et al.

    The rapid discovery of functional coatings is vital for advancing technologies in healthcare, energy, and environmental protection, yet it remains limited by the lack of scalable high‐throughput (HT) methods. Here, an ultra‐high‐throughput (UHT) combinatorial strategy is introduced for the miniaturized synthesis and screening of polyamine‐polyphenolic ( PaPp ) coatings (formed in Tris buffer) using droplet microarrays (DMA). Approximately 30 000 coatings were generated from binary and ternary combinations of 51 polyphenols ( Pp ) and 12 polyamines ( Pa ), each produced in 160 nL volumes (Pseudomonas aeruginosa , and subsequent validation on macroscale substrates confirmed up to P. aeruginosa and E. coli . Importantly, five coatings exhibited multiple functionalities, combining surface stability, intrinsic fluorescence, metal‐reducing activity, antibacterial effects, and compatibility with adherent human cells. This UHT approach yields the first comprehensive functionality map of PaPp coatings, revealing previously inaccessible multifunctional materials and demonstrating a scalable strategy for the discovery of surface chemistries with tailored optical, redox, and biological properties.


  • Open Access

    Parallel 3D Bioprinting on SLIPS‐Microarrays

    by Julius von Padberg, Julian A. Serna, Maike Schliephake, Pavel A. Levkin

    Parallelization remains a key challenge in advancing three‐dimensional (3D) bioprinting from a prototyping method to a practical tool for true high‐throughput screening (HTS). HTS requires arrays of physiologically relevant 3D tissue models that remain viable under immersion in liquid. Yet current 3D bioprinting on liquid compartmentalization platforms is inherently serial. Sequential fabrication scales unfavorably with the array sizes required for ever‐growing libraries in disease modeling and drug discovery, forcing a trade‐off between physiological relevance and throughput. Here, we present a parallel 3D bioprinting solution that integrates Digital Light Processing (DLP) stereolithography with a wettability‐patterned slippery liquid‐infused porous surface (SLIPS) ‐ Droplet Microarray (DMA). This wall‐less compartmentalization platform repels gelatin methacryloyl (GelMA) inks and maintains stable droplet boundaries, enabling complete postprinting immersion of hydrogel structures in liquid droplets. By eliminating the physical solid walls between compartments, it becomes possible to fabricate arrays of 3D hydrogel structures in parallel, effectively decoupling fabrication time from array size. Thus, this work bridges the gap between 3D tissue‐model arrays and fabrication speed required for HTS. Using optimized printing parameters, we fabricate tens to hundreds of cell‐laden GelMA structures within 10 min, preserving cell viability and compartmentalization. Our parallel 3D printing– SLIPS–DMA approach establishes a flexible system‐on‐a‐chip for miniaturized multicondition HTS of cell–material–drug interactions.

  • Open Access

    Solid Medium Droplet Microarray for Miniaturized Antimicrobial Susceptibility Test

    by Yuliang Shao, Nikolaj K. Mandsberg, Wenxi Lei, Thomas Schwartz, Pavel A. Levkin, Anna A. Popova

    Antimicrobial susceptibility testing (AST) that is easily adaptable for point‐of‐care (POC) use is essential for addressing the growing threat of antibiotic resistance. Here, the solid medium droplet microarray (SM‐DMA), a simple yet versatile testing platform consisting of a single microscope slide patterned with an array of 80 agar droplets (6–8 μL each), containing customizable combinations of clinically relevant antibiotics, is introduced. The test allows for easy manual sample application and features a colorimetric self‐check readout. Using E. coli (DSM498) as a model organism, accurate determination of minimum inhibitory concentrations for clinically relevant antibiotics (cefotaxime, ciprofloxacin, and ampicillin), producing results consistent with EUCAST clinical breakpoints, is demonstrated. Furthermore, SM‐DMA facilitates combinatorial antibiotic testing, represented by intuitive viability heatmaps. The platform is more time efficient (≈16–18 h total) compared to the conventional agar plate‐based methods. Owing to the robustness, ease of use, and independence from specialized equipment, the SM‐DMA can be adapted for POC applications by nontrained personnel or even by patients themselves.

  • Open Access

    Multiplexed Fluorescent Microarrays on MIL‐101(Cr) Thin Films as Luminescent Probes for pH and Disease‐Associated Molecules

    by Wenjing Wang, Wenwu Yang, Maike Schliephake, Tonghan Zhao, Yan Liu, Navid Hussain, Ben Breitung, Andreas H. Schäfer, Pavel A. Levkin, Jasmin Aghassi‐Hagmann, et al.

    Recently, metal‐organic frameworks (MOFs) have shown high potential in the field of sensing. However, fluorescent‐based detection with MOFs in solution needs complex pre‐treatments and has stability issues, complicating measurements and handling for sensing applications. Here, an easy‐to‐handle and low‐cost strategy is introduced to convert MOF‐based sensing from solution to surface using scanning probe lithography. The MOF is immobilized on the surface by receding meniscus coating, and then fluorescent dyes are patterned on the MOF thin films through microchannel cantilever spotting to generate dye@MOF fluorescent microarrays, which are stable in analyte solutions. The dye@MOF fluorescent microarrays exhibit good pH sensitivity in the pH 5–9 range, and dopamine can be distinguished from three other metabolites in the solution by these microarrays when signals from different dyes are analyzed in combination with principal component analysis. This concept provides a new approach for stable microarray‐based detection of small molecule analytes from a fluid environment.

  • Open Access

    Ultra‐High‐Throughput Nanoliter‐Scale Liquid‐Liquid Extractions and Reaction Mixture Purification

    by Michelle J. Iwohn, Janne J. Wiedmann, Pavel A. Levkin

    Miniaturizing chemical processes to the nanoliter scale is essential for reducing costs, increasing throughput, and enabling massively parallel experimentation with tens of thousands of samples. However, purification at this scale remains a major issue. Conventional methods like liquid‐liquid extraction (LLE) are not applicable at nanoliter volumes without expensive and complex instrumentation, and even then, not at such extreme throughput. The droplet microarray (DMA) platform enables high‐throughput synthesis in nanoliter droplets confined to hydrophilic spots on a superhydrophobic surface. Yet, purification of compounds at this small scale and high throughput remains challenging. Here, a novel approach is presented for parallel purification of thousands of microliter‐ to nanoliter‐sized droplets via LLE. The method exploits the ability of hydrophilic spots to retain aqueous droplets under both air and organic solvents. By immersing the entire DMA into an organic solvent, all droplets simultaneously contact the organic phase, enabling rapid, parallel, single‐step extraction across the entire array. This process eliminates the need for individual pipetting or complex phase separation equipment, making it scalable, cost‐effective, and compatible with miniaturized, ultra‐high‐throughput workflows down to 15 nL volume and up to tens of thousands of parallel extractions.


  • Open Access

    Nanodroplet‐Array‐Plattform zur integrierten Synthese und Screening von MEK Inhibitoren: Ein miniaturisierter Ansatz für die frühe Pharmaforschung

    by Maximilian Seifermann, Julius Höpfner, Liana Bauer, Divya Varadharajan, Stefan Schmidt, Björn Fröhlich, Benjamin Wellenhofer, Charlotte Luchena, Carsten Hopf, Anna A. Popova, et al.

    Zusammenfassung: Die frühe Pharmaforschung wird geprägt von Hochdurchsatz‐Screenings, die jedoch kostenintensiv und zeitaufwendig sind und somit den Zugan für akademische Labore und kleine Unternehmen limitiert. Ein zentraler Engpass liegt in der fehlenden Miniaturisierung sowie der Trennung der Substanzsynthese vom biologischen Screening. Wir präsentieren eine Nanodroplet‐Array‐Plattform, die die Synthese, Charakterisierung und zellbasierte Testung von 325 MEK‐Inhibitoren (Mitogen‐aktivierte‐Protein‐Kinase‐Kinase) integriert. Ziel ist der MAPK/ERK‐Signalweg (Mitogen‐aktivierte Protein‐Kinase/Extracellular‐signal regulated kinases), der eine Schlüsselrolle in Darm‐ und Bauchspeicheldrüsenkrebs spielt. Die Plattform ermöglicht die On‐Chip‐Synthese, MALDI‐MSI‐(Matrix‐unterstützte‐Laser‐Desorption/Ionisation‐Massenspektrometrie‐Imaging)‐Charakterisierung und das zellbasierte Screening in 200 nL Tropfen, die 20 nmol Edukt enthielten (∼4 ng des Produktes), und jeweils 300 Zellen pro Tropfen. Beim Screening wurden 46 Verbindungen mit erhöhter Zytotoxizität im Vergleich zu Mirdametinib, einem klinisch zugelassenen MEK‐Inhibitor, identifiziert. Molekulare Docking Analysen wiesen einen ähnlichen allosterische Bindungsmechanismus zu Mirdametinib vor, was auf eine nicht‐kompetitive ATP‐Hemmung hindeutet. Innerhalb von sieben Tagen wurde die Synthese und das Screening der 325 Substanzen ermöglicht. Dafür wurden weniger als 10 mg Edukt, 250 µL Lösungsmittel und etwa 100 µL Zellsuspension (∼100.000 Zellen) verbraucht. Diese Forschung zeigt das Potenzial der Integration von miniaturisierter kombinatorischer Synthese und biologischem Screening auf, sodass die Plattform einen effizienteren, zugänglicheren und ressourcenschonenderen Ansatz für die frühe Pharmaforschung ermöglicht.

  • Open Access

    Nanodroplet Array Platform for Integrated Synthesis and Screening of MEK Inhibitors: a Miniaturized Approach to Early Drug Discovery

    by Maximilian Seifermann, Julius Höpfner, Liana Bauer, Divya Varadharajan, Stefan Schmidt, Björn Fröhlich, Benjamin Wellenhofer, Charlotte Luchena, Carsten Hopf, Anna A. Popova, et al.

    Early‐stage drug discovery relies on high‐throughput screenings, which are costly and time‐intensive, limiting access for academic laboratories and small companies. A key bottleneck is the lack of miniaturization and the separation of compound synthesis from screening. We present a nanoliter droplet array platform integrating synthesis, characterization, and cell‐based screening of 325 MEK (mitogen‐activated protein kinase kinase) inhibitors, targeting the MAPK/ERK (mitogen‐activated protein kinase/extracellular signal‐regulated kinase) pathway, implicated in colorectal and pancreatic cancer. The platform enables on‐chip synthesis, MALDI‐MSI (matrix‐assisted laser desorption/ionization‐mass spectrometry imaging) characterization, and cell‐based screening within 200 nL droplets containing 20 nmol starting material (∼4 ng final compound), and only 300 cells per droplet. Screening identified 46 compounds with higher cytotoxicity than mirdametinib, a clinically approved MEK inhibitor. Molecular docking revealed a shared allosteric binding mechanism, indicating non‐competitive ATP inhibition. Synthesis and screening of all 325 compounds were completed within 7 days, requiring <10 mg of reactants, <250 µL solvent, and ∼100 µL of cell suspension (∼100,000 cells in total). Our results demonstrate that integrating miniaturized combinatorial synthesis and biological screening in a single platform can accelerate early‐stage drug discovery while reducing cost and resource use.


  • Open Access

    Rational Design of Unsaturated, Thioether Ionizable Lipids for Enhanced In Vivo mRNA Delivery

    by Eleni Samaridou, Johanna Simon, Moritz Beck‐Broichsitter, Gary Davidson, Pavel A. Levkin

    Safe and functional delivery of delicate mRNA molecules to target tissues is a crucial step in the development of effective vaccines and therapeutic interventions. Lipid nanoparticles (LNP) are the most clinically advanced delivery vehicles for mRNA drugs and crucially rely on ionizable cationic lipids. However, the structure‐function relationships between ionizable lipids and efficient in‐vivo mRNA delivery remain poorly understood. Here, we focus on the rational design and sequential structural optimization of our ionizable lipids that performed well in vitro, but not in vivo. Through two distinct iterative optimization cycles—targeting the lipid tail and the headgroup—we studied how fusogenicity and pKa of ionizable lipids contribute to LNP delivery performance, in vivo. By engineering lipids with both unsaturated tails and more hydrophobic amino headgroups, we achieved both significant improvement of protein expression in vitro, reduced hemolysis risk, and more than 200‐fold improvement of in vivo mRNA delivery. When compared head‐to‐head to a market‐approved LNP benchmark, the newly developed ionizable lipids/LNP resulted in equally highly efficient in vivo mRNA delivery, with strong liver and spleen tropism upon intravenous injection, while matching the safety of the approved platform. Our findings are pivotal for the development of next‐generation mRNA‐LNP therapies and vaccines.


  • Open Access

    UV‐Induced Photopatterning of the Thermoresponsive Properties of a Poly(ethylene glycol)methylether acrylate‐co‐poly(N‐isopropylacrylamide) Hydrogel

    by Qian‐Pu Cheng, Nikolaj K. Mandsberg, Pavel A. Levkin, Shan‐Hui Hsu

    Photopatterning offers a versatile and precise approach for modifying surface properties, making it a valuable technique in material design. Recent research demonstrates that polymer swelling can significantly enhance photodegradation, facilitating topographical patterning. Herein, this concept in stimuli‐responsive hydrogels is explored, focusing on the thermoresponsive poly(ethylene glycol) methylether acrylate‐co‐poly(N‐isopropylacrylamide) (PPEGA–PNIPAM) hydrogel. Surprisingly, it is observed that UV exposure not only partially degrades the hydrogel but also diminishes its thermal responsiveness. This effect enables selective deactivation of responsive properties of the PPEGA–PNIPAM, allowing for spatially defined variations in thermomechanical behavior through photolithography. By using these spatial differences, the hydrogel is programmatically transformed into a thermoresponsive actuator via a single‐step photopatterning process, demonstrating a potential application of UV‐induced change of thermoresponsiveness. Furthermore, incorporating gelatin methacrylate enhances biocompatibility, suggesting new possibilities for developing thermoresponsive bioactuators. Thus, the results demonstrate the potential of UV‐induced modulation of stimuli‐responsive properties of hydrogels and present new opportunities for creating multifunctional materials with tailored properties.